Thomas Nutman, MD (NIAID)
Total Page:16
File Type:pdf, Size:1020Kb
Great Neglected Diseases Network • Started by the Rockefeller Foundation in 1977 • First and only director Kenneth Warren • Networks of 14 research units across the world (US, UK, Egypt, Australia, Israel, Sweden, Mexico, Brazil, Thailand) – Multidisciplinary – Emphasis on research - immunology, biochemistry, molecular biology, genetics – Disease focus – parasitic infections including malaria • Lasted only 8 years – But spawned the careers of a generation of parasite-oriented scientists The Millenium Development Goals 1. Eradicate extreme poverty and hunger 2. Achieve universal primary education 3. Promote gender equality and empower women 4. Reduce child mortality 5. Improve maternal health 6. Combat HIV/AIDS, malaria and other diseases 7. Ensure environmental sustainability 8. Develop a global partnership for 2000-2015 MDGs development From GNDs to Neglected Tropical Diseases (NTDs) • Attributed to and popularized by – Peter Hotez – David Molyneux – Alan Fenwick • Grew out of frustration from the use of the term “Other Diseases” in MDG #6 as it – created a two-tier system (HIV, malaria vs everything else) – made public advocacy for these “other diseases” impossible – left out these “other diseases” in most discussions on global health • NTD “marketing” has driven funding worldwide The Neglected Tropical Diseases (NTDs) • The most prevalent infections of poor people – Up to half of the 2.7 billion people who live on less than $2 per day • Non-emerging ancient conditions • Indigenous populations • Chronic disabling conditions – Growth delays – Blindness – Disfigurement – Stigma • Poverty promoting conditions – Child development and education – Pregnancy outcome – Productive capacity The 10 Leading Causes of Life-Years Lost to Disability and Premature Death Lower respiratory tract infections 91.4 HIV-AIDS 84.5 Unipolar depression 67.3 Diarrheal diseases 62.0 Ischemic heart diseases 58.6 Neglected tropical diseases 56.6 Cerebrovascular diseases 49.2 Malaria 46.5 Road traffic accidents 38.7 Tuberculosis 34.7 0 20 40 60 80 100 Disability-Adjusted Life-Years (millions) The Neglected Tropical Diseases Scabies Snakebites Mycetoma and other deep mycoses Loiaisis Common Human Helminth Infections Schistosoma mansoni Echinococcus, Taenia spp >200 million infected >100 million infected Cestodes Brugia malayi Ancylostoma duodenale Onchocerca volvulus Nector americanus Wuchereria bancrofti Trematodes 576 million infected 157 million infected Nematodes Strongyloides stercoralis Ascaris lumbricoides 50-100 million infected >1 billion infected Trichinella spiralis Trichuris trichiura >600 million infected Babu and Nutman, Clin Immunol, 2017 Filarial Infections of Humans Infection Disease Number Wolbachia infected Wuchereria bancrofti Lymphatic Filariasis 120 million Yes Brugia spp. Lymphatic Filariasis 10 million Yes Onchocerca volvulus Onchocerciasis 29 million Yes Loa loa Loiasis 13 million No Mansonella ozzardi Mansonellosis ? Yes Mansonella perstans Perstans Filariasis ~90 million Yes Mansonella streptocerca Streptocerciasis ? ? Collectively 2nd leading cause of disability worldwide (>1.2 million DALYs lost) Loiasis • Ogranism-Loa loa • Vector - Chrysops spp. (deerfly) • Microfilariae: Blood-borne • Adult worms: subcutaneous • Prevalence - 13 million • Geographic Distribution - West and Central Africa • Host range - Human Geographic distribution of Loa loa infection Lifecycle of Loa loa (EGG) L1 ADULT L4 L2 L3 Loiasis - Clinical Manifestations • Asymptomatic (subclinical) • Non-specific – urticaria, pruritus, myalgias • Calabar swellings • Eyeworm • Complications – Endomyocardial fibrosis, renal disease, encephalopathy, entrapment neuropathy Loiasis – Calabar Swellings •Episodic angioedema •Most common on extremities •Duration -1-4 days Loiasis - Eyeworm Clinical differences between endemic and non-endemic patients with loiasis Manifestation Expatriate Endemic (Benin) N=42 N=51 Calabar swelling 80% 16% Eyeworm 10% 16% Asymptomatic 16% 74% Nonspecific Urticaria/myalgia/artrhralgia 54% ??? Complications Hematuria/proteinuria 21% 22% Endomyocardial fibrosis 2% ??? . Klion, A.D., A. Massougbodji, B.C. Sadeler, E.A. Ottesen, and T.B. Nutman. 1991 J Infect Dis 163:1318-1325 Clinical differences between endemic and non-endemic patients with loiasis Manifestation Expatriate Endemic N=144 N=37 Calabar swelling* 80% 15% Eyeworm* 14% 62% Asymptomatic (MF+)* 22% 74% Nonspecific Urticaria* 19% 2% Myalgia/arthralgia 22% 11% Dermatitis 24% 16% Lymphadenopathy* 11% 2% Herrick JA et al.Clin Infect Dis. 2015 ;60:684-693. Complications associated with Loa loa infection Manifestation Expatriate Endemic N=144 N=37 Hematuria/proteinuria 21% 22% Endomyocardial fibrosis 0.4% 0% Neuropsychiatric 0.4% 0% Pulmonary 2% 3% Herrick JA et al.Clin Infect Dis. 2015 ;60:684-693. Eosinophilic endomyocardial fibrosis in a patient with loiasis H and E Anti-Eo-MBP Modulation of Immune Response to Filarial Infection as a Function of Time Anti-filarial Eosinophils Chemotherapy IgE IgG4 Antibody and Eosinophil Responses Eosinophil and Antibody Response to Response to Bystander Anti-filarial Parasite Antigens Antigens/Allergens/Vaccines Chemotherapy Anti-IL-10 in vitro Life Cycle of Lymphatic Filariae CD4+ T Cell Responses Cell T CD4+ (EGG) L1 Life Cycle of Lymphatic Filariae ADULT 0 6 months 6 months Decades L2 (EGG) L4 L1 Early Infection Chronic Infection ADULT L3 Life Cycle of Lymphatic Filariae + L4 L2 (EGG) L1 L3 ADULT L4 L2 L3 Immune Responses as a Function of Time in Human Helminth Infection Response to bystander antigen/vaccines/allergens IgE/IgG1 Th1 TNF-a Response to parasite antigen IFN-g IgE/IgG4 Th17 IL-17 to parasite antigen MACs AAMs IL-4 Monos DCs Response IL-5 Eos Th2 IL-13 ILCs IL-10 AAMs NKs Tregs IL-10 Baso/ IL-10 MC Tregs TGF-b IL-10 TGF-b TCM Teff InItiation and Development Patency establIshment of adult of InfectIon worms Decades 0 2 weeks Up to 6 months // // Parasite Host Uncontrolled response Modulated response Pro-inflammatory Tolerant/suppressed -10 Immune-mediated pathology IL Patent subclinical Lympahtic Filariasis Onchocerciasis infection Loiasis Loiasis: treatment • Diethylcarbamazine (DEC) – treatment of choice – mechanism of action unknown – macro- and microfilaricidal – associated with severe side effects in patients with high levels of circulating microfilariae • Ivermectin – microfilaricidal – also associated with severe side effects in patients with high microfilarial levels Loiasis: adjunct therapy • Corticosteroids – decrease rate of microfilarial clearance – reduce severity of post-treatment reactions – DO NOT prevent severe CNS complications of treatment in patients with high microfilarial loads • Apheresis – transient reduction of microfilarial load – ?decreased incidence of severe side effects Filarapheresis From 1990 - present Efficiency of filarapheresis • Numbers – 46 heavily microfilaremic patients – 68 procedures • Often on successive days • Issues – Must be done at midday Average reduction 67% Periodicity of various microfilariae in blood Wb Ll Di Wb var Pac The Loa loa Genome Ce III Ll Wb Bm Chromosome Genes mapped Extraordinary degree of synteny among the filariae Number to largest scaffolds Desjardins et al Nature Genetics 2013 Worm kinases that are targets of FDA-approved drugs hapla malayi pacifica spriralis Classification FPKM Approved drugs L. loa W. bancrofti B. A. suum P. C. elegans C.briggsae M. T. AGC/DMPK/ROCK 58.18 1 1 2 1 0 1 1 1 1 Fasudil ATYPICAL/PIKK/FRAP 2 1 3 1 2 1 1 1 2 Temsirolimus TK/ABL 18.87 1 1 1 1 1 1 1 1 1 Imatinib, Nilotinib, Dasatinib TK/EGFR 0.18 1 1 1 2 1 1 1 1 1 Gefitinib, Erlotinib, Lapatinib TK/SRC 40.86 1 1 1 1 1 1 1 1 1 Dasatinib TKL/RAF/RAF 27.55 1 1 2 1 1 1 1 1 1 Sonafenib Structural similarity between the filarial abl- like kinase and the human Bcr-abl oncogene Loa loa Abl-like kinase Human Bcr-Abl 100.0100 LoaLoaAbl loa protein NAN WuchereriaW.banc.Abl bancrofti protein 62.162.1A Brugiabmaabl malayi protein 100.0100 AscarisA.suum suum Abl 92.492.4 Homohuman sapiens abl protein TrichinellaTspiralis spiralis protein SchistosomaSmaAbl mansoniprotein 79.279.2 70 60 50 40 30 20 10 0 70 60 50 40 30 20 10 0 AminoAmino Acid Acid Substitution Substitution per 100100 Residues residues Bootstrap(Bootstrap Trials Trials = =1000, 1000, Seed seed = 111) = 111 Repurposing imatinib for antifilarial chemotherapy L3 killing by imatinib Imatinib 0µM 100 100uM 80 50uM l a 25uM v i 60 v 10uM r u 5uM 40 S 0uM % 20 0 0 1 2 3 4 Days of exposure to imatinib Mf killing by imatinib 100 100uM 80 50uM l a 25uM v i 60 v 10uM r u 5uM 40 S 0uM % 20 0 Imatinib 50µM 0 1 2 3 4 Days of exposure to imatinib O’Connell EM et al, JID 2015 Filarial c-abl Localizes Most Strongly to the Female Reproductive Tract of the Filariae DAPI SHG Anti-cABL Merge Fertilized ova Fertilized Morula stage Morula Pretzel stage Pretzel Isotype control O’Connell EM, et al. PLoS NTD, 2017 Clinical Protocol to Establish Efficacy and Safety of Single Dose Imatinib in Loa loa Microfilaremia Randomized-controlled dose escalation trial of imatinib, evaluating the kinetics of Loa loa microfilarial (MF) response over 1 year in Cameroon Severe adverse reactions (encephalopathy, death) to ivermectin is related to the Loa loa MF count and the rapidity with which it works 60000 >20000 MF/mL 40000 Danger zone Ivermectin Desired Drug Microfilariae 20000 0 0 2 4 6 8 Days Proposed use: Give drug for routine mass Drug given drug administration (MDA) during MF nadir to avoid severe reactions. It Takes a Village Large Community.